Gelonghui, January 19 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that injectable GenSci 125 was independently developed by Jinsai Pharmaceutical and is the first injectable long-term progesterone weekly preparation approved by the FDA for clinical research.
长春高新(000661.SZ)：注射用GenSci125 为金赛药业自主研发
Changchun Hi-Tech (000661.SZ): Injectable GenSci125 independently developed for Jinsai Pharmaceutical
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.